MedTrace Logo

Brain PERfusion Evaluation by Contrast-Enhanced UltraSound

NCT05893407 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2025-06-19

No results posted yet for this study

Summary

The objective of the study is to assess brain tissue perfusion by contrast-enhanced ultrasound perfusion imaging (PerCEUS) in acute brain injuries. More precisely, it aims :

* to evaluate the heterogeneity of brain perfusion and thus diagnose brain tissue hypoperfusion with contrast-enhanced ultrasound.
* to correlate contrast-enhanced ultrasound with perfusion measurements by usual multimodal monitoring.

Conditions

  • Cerebral Hemorrhage
  • Subarachnoid Hemorrhage
  • Ischemic Stroke
  • Cerebrovascular Circulation
  • Perfusion

Interventions

DIAGNOSTIC_TEST

Measuring contrast-enhanced ultrasound perfusion with phase inversion harmonic imaging

Contrast-enhanced ultrasound perfusion imaging (PerCEUS) will be performed by a dedicated study team. The transcranial color duplex sonography will be performed with a 1-5 MHz dynamic sector array (S5-1) from a Philips Epiq 7 ultrasound machine (Philips Healthcare, Andover, MA). The field-of-view will be set to an imaging depth of 150 mm in a sector angle of 90°. The imaging plane will be then tilted to the diencephalic, in which the frontal horns of the side ventricles and the third ventricle serve as landmarks and where the anterior and posterior middle cerebral artery (MCA) territory and the basal ganglia (BG) as region of interest could be identified without artefacts from major vessels. High mechanical index bolus imaging will be performed from the sanest side of the head. Data acquisition of 45 seconds will be recorded immediately after the beginning of the contrast ultrasound imaging, using a mechanical index (MI) setting of 1.1 and a frame rate of 33 Hz.

Sponsors & Collaborators

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Romain BARTHELEMY, MD · AP-HP Lariboisière Hospital, Department of Anaesthesia and Intensive Care

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-21
Primary Completion
2025-07-31
Completion
2025-07-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05893407 on ClinicalTrials.gov